FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600903904> ?p ?o ?g. }

• W2600903904 endingPage "1141" @default.
• W2600903904 startingPage "1132" @default.
• W2600903904 abstract "Essentials•Low risk patients don't require venous thromboembolism (VTE) prophylaxis; low risk is unquantified.•We used a Markov model to estimate the risk threshold for VTE prophylaxis in medical inpatients.•Prophylaxis was cost‐effective for an average medical patient with a VTE risk of ≥ 1.0%.•VTE prophylaxis can be personalized based on patient risk and age/life expectancy.Summary: BackgroundVenous thromboembolism (VTE) is a common preventable condition in medical inpatients. Thromboprophylaxis is recommended for inpatients who are not at low risk of VTE, but no specific risk threshold for prophylaxis has been defined.ObjectiveTo determine a threshold for prophylaxis based on risk of VTE.Patients/MethodsWe constructed a decision model with a decision‐tree following patients for 3 months after hospitalization, and a lifetime Markov model with 3‐month cycles. The model tracked symptomatic deep vein thromboses and pulmonary emboli, bleeding events and heparin‐induced thrombocytopenia. Long‐term complications included recurrent VTE, post‐thrombotic syndrome and pulmonary hypertension. For the base case, we considered medical inpatients aged 66 years, having a life expectancy of 13.5 years, VTE risk of 1.4% and bleeding risk of 2.7%. Patients received enoxaparin 40 mg day−1 for prophylaxis.ResultsAssuming a willingness‐to‐pay (WTP) threshold of $100 000/ quality‐adjusted life year (QALY), prophylaxis was indicated for an average medical inpatient with a VTE risk of ≥ 1.0% up to 3 months after hospitalization. For the average patient, prophylaxis was not indicated when the bleeding risk was > 8.1%, the patient's age was > 73.4 years or the cost of enoxaparin exceeded $60/dose. If VTE risk was < 0.26% or bleeding risk was > 19%, the risks of prophylaxis outweighed benefits. The prophylaxis threshold was relatively insensitive to low‐molecular‐weight heparin cost and bleeding risk, but very sensitive to patient age and life expectancy.ConclusionsThe decision to offer prophylaxis should be personalized based on patient VTE risk, age and life expectancy. At a WTP of $100 000/QALY, prophylaxis is not warranted for most patients with a 3‐month VTE risk below 1.0%. Essentials•Low risk patients don't require venous thromboembolism (VTE) prophylaxis; low risk is unquantified.•We used a Markov model to estimate the risk threshold for VTE prophylaxis in medical inpatients.•Prophylaxis was cost‐effective for an average medical patient with a VTE risk of ≥ 1.0%.•VTE prophylaxis can be personalized based on patient risk and age/life expectancy. •Low risk patients don't require venous thromboembolism (VTE) prophylaxis; low risk is unquantified.•We used a Markov model to estimate the risk threshold for VTE prophylaxis in medical inpatients.•Prophylaxis was cost‐effective for an average medical patient with a VTE risk of ≥ 1.0%.•VTE prophylaxis can be personalized based on patient risk and age/life expectancy. Venous thromboembolism (VTE) is a common preventable condition in medical inpatients. Thromboprophylaxis is recommended for inpatients who are not at low risk of VTE, but no specific risk threshold for prophylaxis has been defined. To determine a threshold for prophylaxis based on risk of VTE. We constructed a decision model with a decision‐tree following patients for 3 months after hospitalization, and a lifetime Markov model with 3‐month cycles. The model tracked symptomatic deep vein thromboses and pulmonary emboli, bleeding events and heparin‐induced thrombocytopenia. Long‐term complications included recurrent VTE, post‐thrombotic syndrome and pulmonary hypertension. For the base case, we considered medical inpatients aged 66 years, having a life expectancy of 13.5 years, VTE risk of 1.4% and bleeding risk of 2.7%. Patients received enoxaparin 40 mg day−1 for prophylaxis. Assuming a willingness‐to‐pay (WTP) threshold of $100 000/ quality‐adjusted life year (QALY), prophylaxis was indicated for an average medical inpatient with a VTE risk of ≥ 1.0% up to 3 months after hospitalization. For the average patient, prophylaxis was not indicated when the bleeding risk was > 8.1%, the patient's age was > 73.4 years or the cost of enoxaparin exceeded $60/dose. If VTE risk was < 0.26% or bleeding risk was > 19%, the risks of prophylaxis outweighed benefits. The prophylaxis threshold was relatively insensitive to low‐molecular‐weight heparin cost and bleeding risk, but very sensitive to patient age and life expectancy. The decision to offer prophylaxis should be personalized based on patient VTE risk, age and life expectancy. At a WTP of $100 000/QALY, prophylaxis is not warranted for most patients with a 3‐month VTE risk below 1.0%." @default.
• W2600903904 created "2017-04-07" @default.
• W2600903904 creator A5007153736 @default.
• W2600903904 creator A5028348427 @default.
• W2600903904 creator A5030444507 @default.
• W2600903904 creator A5084348847 @default.
• W2600903904 date "2017-06-01" @default.
• W2600903904 modified "2023-10-14" @default.
• W2600903904 title "A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients" @default.
• W2600903904 cites W1248879196 @default.
• W2600903904 cites W1511757448 @default.
• W2600903904 cites W1591411731 @default.
• W2600903904 cites W1946283557 @default.
• W2600903904 cites W1971787812 @default.
• W2600903904 cites W1971862934 @default.
• W2600903904 cites W1978802836 @default.
• W2600903904 cites W1979871017 @default.
• W2600903904 cites W1980480088 @default.
• W2600903904 cites W1986551763 @default.
• W2600903904 cites W2002347984 @default.
• W2600903904 cites W2006737170 @default.
• W2600903904 cites W2012519169 @default.
• W2600903904 cites W2021161895 @default.
• W2600903904 cites W2023603983 @default.
• W2600903904 cites W2027716997 @default.
• W2600903904 cites W2033102959 @default.
• W2600903904 cites W2033228742 @default.
• W2600903904 cites W2034457279 @default.
• W2600903904 cites W2036804810 @default.
• W2600903904 cites W2043772350 @default.
• W2600903904 cites W2055974666 @default.
• W2600903904 cites W2059775530 @default.
• W2600903904 cites W2067254496 @default.
• W2600903904 cites W2072975396 @default.
• W2600903904 cites W2074335635 @default.
• W2600903904 cites W2074381684 @default.
• W2600903904 cites W2076621544 @default.
• W2600903904 cites W2100956551 @default.
• W2600903904 cites W2102778065 @default.
• W2600903904 cites W2105079657 @default.
• W2600903904 cites W2109524995 @default.
• W2600903904 cites W2110992040 @default.
• W2600903904 cites W2113816765 @default.
• W2600903904 cites W2117983655 @default.
• W2600903904 cites W2122644025 @default.
• W2600903904 cites W2127086872 @default.
• W2600903904 cites W2131099415 @default.
• W2600903904 cites W2136587148 @default.
• W2600903904 cites W2140611397 @default.
• W2600903904 cites W2140707981 @default.
• W2600903904 cites W2148287985 @default.
• W2600903904 cites W2152393713 @default.
• W2600903904 cites W2156573757 @default.
• W2600903904 cites W2163451556 @default.
• W2600903904 cites W2166345657 @default.
• W2600903904 cites W2271427560 @default.
• W2600903904 cites W2313923699 @default.
• W2600903904 cites W2340367584 @default.
• W2600903904 cites W2340796010 @default.
• W2600903904 cites W2342069276 @default.
• W2600903904 cites W2354196758 @default.
• W2600903904 cites W4211082423 @default.
• W2600903904 cites W4240251982 @default.
• W2600903904 cites W4297991826 @default.
• W2600903904 cites W2973759191 @default.
• W2600903904 doi "https://doi.org/10.1111/jth.13687" @default.
• W2600903904 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5712445" @default.
• W2600903904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28371250" @default.
• W2600903904 hasPublicationYear "2017" @default.
• W2600903904 type Work @default.
• W2600903904 sameAs 2600903904 @default.
• W2600903904 citedByCount "14" @default.
• W2600903904 countsByYear W26009039042018 @default.
• W2600903904 countsByYear W26009039042019 @default.
• W2600903904 countsByYear W26009039042021 @default.
• W2600903904 countsByYear W26009039042022 @default.
• W2600903904 countsByYear W26009039042023 @default.
• W2600903904 crossrefType "journal-article" @default.
• W2600903904 hasAuthorship W2600903904A5007153736 @default.
• W2600903904 hasAuthorship W2600903904A5028348427 @default.
• W2600903904 hasAuthorship W2600903904A5030444507 @default.
• W2600903904 hasAuthorship W2600903904A5084348847 @default.
• W2600903904 hasBestOaLocation W26009039041 @default.
• W2600903904 hasConcept C12174686 @default.
• W2600903904 hasConcept C126322002 @default.
• W2600903904 hasConcept C133925201 @default.
• W2600903904 hasConcept C177713679 @default.
• W2600903904 hasConcept C187212893 @default.
• W2600903904 hasConcept C194828623 @default.
• W2600903904 hasConcept C2776265017 @default.
• W2600903904 hasConcept C2776688490 @default.
• W2600903904 hasConcept C2778959117 @default.
• W2600903904 hasConcept C2780868729 @default.
• W2600903904 hasConcept C2908647359 @default.
• W2600903904 hasConcept C2991741193 @default.
• W2600903904 hasConcept C38652104 @default.
• W2600903904 hasConcept C41008148 @default.
• W2600903904 hasConcept C71924100 @default.

• next